We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Use of Signal Transduction Inhibitors to Treat Cancer in Children Questioned

By Biotechdaily staff writers
Posted on 24 Mar 2008
A drug that had been found effective for treating medulloblastoma, a type of brain tumor found mostly in children, in a mouse model has now been found to cause permanent bone damage in young mice and may not be appropriate for use in human children.

In 2004 researchers treated mice from a line that had been genetically engineered to develop medulloblastoma with oral doses of HhAntag, a signal transduction inhibitor (STI) known to block the function of a molecule called smoothened (Smo). More...
The suppression of Smo also suppressed several genes that are critical to triggering and driving tumor growth. The compound inhibited cell proliferation and led to the death of tumor cells, resulting in regression of the medulloblastoma. The Smo protein is part of a biochemical cascade of reactions called the Sonic Hedgehog pathway (Shh). The Shh pathway triggers normal growth of the cerebellum in the fetus, but abnormal activity during infancy and early childhood causes medulloblastoma. The hedgehog pathway does not function in tumor cells cultured in dishes: only animal studies were able to show that HhAntag could halt and reverse an otherwise fatal cancer.

In the current study, investigators at The Children's Hospital of Philadelphia (PA, USA) tested HhAntag on young mice, 10 to 14 days old, in contrast to the adult mice tested previously. They reported in the March 2008 issue of the journal Cancer Cell that when examined after only four doses of the drug, the treated mice were found to be smaller with lower weight and shorter bones than untreated mice, and the effects were not reversible.

"We already knew that the same biological pathway involved in the growth of tumors was also involved in bone development,” said senior author Dr. Tom Curran, professor of developmental biology at The Children's Hospital of Philadelphia, "but we did not expect temporary inhibition to cause an irreversible change in bone growth. While it is not clear that the bone defects we observed in mice would also occur in children, and while signal transduction inhibitors may still represent a highly promising approach to treating pediatric cancer, it may be important to perform pre-clinical testing in young animals before moving ahead to clinical trials. Signal transduction inhibitors such as this drug may still prove beneficial in treating children's cancers, but our findings raise questions about possible adverse effects during childhood development.”


Related Links:
The Children's Hospital of Philadelphia

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Procalcitonin Test
LIAISON B•R•A•H•M•S PCT II GEN
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.